VANCOUVER, Oct. 8 /CNW/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI,
TSX: ANP), a global specialty pharmaceutical and medical device company, today
reported that its corporate partner, Boston Scientific Corporation (NYSE:
BSX), has completed enrollment in the PERSEUS trial, designed to evaluate the
third-generation TAXUS(R) Element(TM) paclitaxel-eluting coronary stent. The
Element Stent platform features the proprietary Platinum Chromium Alloy, and
is designed to enable thinner struts for increased flexibility, a lower
profile and improved radial strength, recoil and radiopacity.
